Helixgate

Helixgate

Uncategorized

Cochrane review dismissing amyloid drugs draws immediate backlash

Published

on

A new report trying to settle a decades-old debate about Alzheimer’s disease has reached a dramatic conclusion: Antibody drugs that target sticky amyloid beta proteins in the brain simply don’t work.

The meta-analysis, which compiles …

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Denali CEO’s ‘greatest professional moment’ arrives as rare disease drug launches

Denali CEO’s ‘greatest professional moment’ arrives as rare disease drug launches

Published

on

After receiving the FDA’s greenlight for Hunter syndrome drug Avlayah, Denali Therapeutics CEO Ryan Watts saw the culmination of 20 years of hard work unraveling the mysteries of the blood-brain barrier.​ ​Read More

Continue Reading

Uncategorized

Why key opinion leader enthusiasm often doesn’t predict future commercial success

Published

on

While prominent physicians can provide companies with valuable guidance during development, their perspective is limited when it comes to projecting how well or how readily a new product will be adopted. Here’s how to perform rigorous commercial diligence.

Continue Reading

Uncategorized

#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring

#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring

Published

on

Roche’s multiple sclerosis pill more than doubled patients’ relapse-free interval compared with Sanofi’s marketed MS pill Aubagio, according to data presented late on Tuesday.

The drug, a BTK inhibitor called fenebrutinib, demonstrated “the lowest relapse …​ ​Read More

Continue Reading
Advertisement

Trending